Just a couple of months ago, I noted that the Treatment Action Campaign in South Africa had urged the Gates Foundation not to proceed with trials comparing stavudine to tenofovir because stavudine is so much more toxic and should simply be replaced by tenofovir forthwith. I noted too how strange this seemed, given that the toxicity of tenofovir is high and well known, as I had noted in several posts; see“HAART is toxic: Mainstream concedes it, in backhanded ways” (2011/12/30).
What will TAC do next, given that the toxicity of tenofovir is becoming talked about increasingly?
What will TAC do next, given that the toxicity of tenofovir is becoming talked about increasingly?
